Ultime notizie per Seres Therapeutics (NASDAQ:MCRB) Azioni

Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/603e4f87b3e2040001080043/tessa-romero">JP Morgan analyst Tessa Romero </a>downgraded the rating for Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Neutral to Underweight. Seres Therapeutics shares closed at $0.7570 on Wednesday. <a href="https://www.benzinga.com/quote/MCRB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas downgraded Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) from Overweight to Neutral and lowered the price target from $230 to $210. Avery Dennison shares closed at $207.65 on Wednesday. <a href="https://www.benzinga.com/quote/AVY/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> downgraded the rating for ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Outperform to Neutral and announced a $340 price target. Icon shares closed at $280.76 on Wednesday. <a href="https://www.benzinga.com/quote/ICLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Andrew Wittmann downgraded WillScot Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) from Outperform to Neutral and maintained the price target of $42. WillScot shares closed at $37.83 on Wednesday. <a href="https://www.benzinga.com/quote/WSC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Brandon Nispel downgraded the rating for Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) from Overweight to Sector Weight. Verizon shares closed at $42.86 on Wednesday. <a href="https://www.benzinga.com/quote/VZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying VZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="541" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-1024x541.png" alt="" class="wp-image-611788" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-1024x541.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-768x406.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233.png 1262w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a></li>
</ul>

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ICLR

MCRB

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

JP Morgan analyst Tessa Romero downgrades Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Neutral to Underweight.

Downgrades

JP Morgan Downgrades Seres Therapeutics to Underweight

Rumors

Watching Seres Therapeutics; Traders Circulate M&A Blog Unconfirmed Rumor That Nestle Has Said To Have Made A Bid Between $6.90-$7.20/Share

Members of the Board,
We are writing to you today as a stockholder of Seres who is seeking additional information regarding the Company's planned sale of its VOWST business to Nestlé Health Science.
We have read a recent media report from Betaville which states that Nestlé S.A. ("Nestlé") approached Seres in July 2024 with an offer to acquire the entire Company for between $6.00 and $6.50 a share. Furthermore, the article states that Seres' Board rejected the offer and instead pursued the sale of the VOWST assets, which was initially announced in June 2024.
This concerns us because Nestlé's offer would have represented a more than 622% premium to the Company's stock price.1 Additionally, it is well known that Seres has been struggling to fund its operations. Investors do not appear to have strong confidence in the Company's ability to turn itself around in the public market, as evidenced by the negative stock price reaction to the August 6, 2024 announcement of the signing of the VOWST sale agreement.2 Nestlé's reported offer could have resulted in a superior outcome for stockholders than the VOWST sale, giving certainty of value to your investors.
If this media report is accurate, that would mean the Board violated its fiduciary duty to stockholders – specifically, its duty to maximize stockholder value – and could be held legally liable. We acknowledge that this information stems from a singular media report, which is why we are asking the Board to provide stockholders with a factual assessment of the contents of the report so that we may make fully informed decisions regarding our investment in the Company.
If you do not address my concerns in a timely fashion, we plan to consider all legal remedies under U.S. federal securities laws, which may potentially include asking a court to void the votes of the Special Meeting of Stockholders based on misleading and incomplete information given to investors.
Time is of the essence, as Seres intends to close the VOWST sale to Nestlé on September 30, 2024. We look forward to hearing from you soon.
Sincerely,
Lucien Selce
&nbsp;
Antoine Khalife
&nbsp;
&nbsp;
MKT Capital Ltd.

Seres Therapeutics Stockholders Publish Open Letter To Board Urging Clarity On Alleged Rejected Nestlé Takeover Offer Of $6.00-$6.50 Per Share Ahead Of VOWST Sale Closing

WIIM

Seres Therapeutics shares are trading higher after the company announced its stockholders voted to approve the previously announced proposed sale of its VOWST business to Société des Produits Nestlé S.A.

<h3>Gainers</h3>
<ul>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock increased by 16.8% to $0.29 during Thursday's after-market session. The company's market cap stands at $6.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock rose 6.69% to $6.16. The market value of their outstanding shares is at $3.1 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) shares moved upwards by 6.01% to $0.88. The company's market cap stands at $134.0 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 5.88% to $1.08. The company's market cap stands at $6.2 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 5.4% to $1.17. The company's market cap stands at $7.1 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 5.2% to $0.26. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares decreased by 27.8% to $0.33 during Thursday's after-market session. The company's market cap stands at $15.9 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock declined by 15.34% to $3.81. The market value of their outstanding shares is at $50.7 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock decreased by 7.04% to $3.7. The market value of their outstanding shares is at $6.5 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares declined by 6.17% to $0.21. The company's market cap stands at $13.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock fell 5.38% to $0.48. The market value of their outstanding shares is at $3.8 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) shares declined by 5.12% to $14.27. The market value of their outstanding shares is at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BIVI

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CHRO

CPHI

LIPO

NVNO

STRM

TBIO

TCBP

TVTX

12 Health Care Stocks Moving In Thursday's After-Market Session

Seres Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>), ("Seres" or the "Company"), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company's VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which details the voting results. The transaction is expected to close on September 30, 2024, subject to the satisfaction of customary closing conditions.

Seres Therapeutics Stockholders Approve Sale Of VOWST To Nestlé Health Science; Sale Expected To Close on September 30

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $10 price target.

Price Target

Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target

Watching Seres Therapeutics; Traders Circulate Unconfirmed M&A Blog Comments Suggesting Nestle Has Offered To Acquire The Company For $750M, Or $6-$6.50/Share

Seres Therapeutics Shares Halted To The Upside; Up 20.00%

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $1.25 price target.

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

Earnings

Seres Therapeutics Q2 2024 GAAP EPS $(0.22) Beats $(0.27) Estimate, $71.2M In Cash And Cash Equivalents That Is Expected To Fund Operations Into The Fourth Quarter Of 2025

Seres Therapeutics shares are trading lower after the company annoucned it signed an agreement with Nestle for the sale of its VOWST business.

In addition, Seres is due to receive installment payments in 2025, as well as potential future payments based on VOWST net sales targets.&nbsp;
Seres will support ongoing VOWST availability by providing transition services through the first quarter of 2025 and manufacturing support through the end of 2025 (subject to limited extension rights by Nestlé) and will continue to share 50/50 in the profit and loss of the business through the end of 2025.&nbsp;

Health Care

Contracts

General

Seres Therapeutics Has Signed An Agreement With Société Des Produits Nestlé For The Sale Of Its VOWST Business To Nestlé Health Science. Seres Will Receive Capital Infusions, Including An Upfront Payment, A Prepaid Milestone Payment, And An Equity Investment

<h3>Gainers</h3>
<ul>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. </li>
<li>Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 18.63% to $1.3. The company's market cap stands at $8.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 35.6% to $0.36 during Monday's regular session. The company's market cap stands at $6.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 31.74% to $3.55. The company's market cap stands at $2.7 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 27.83% to $3.65. The company's market cap stands at $1.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock fell 19.58% to $7.11. The company's market cap stands at $41.9 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock fell 15.0% to $9.3. The market value of their outstanding shares is at $261.0 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 14.62% to $15.52. The company's market cap stands at $2.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNSP

CRIS

CSBR

NNVC

NVAX

RENB

RNAZ

SBFM

SKYE

SMLR

THAR

12 Health Care Stocks Moving In Monday's Intraday Session

Shares of GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to <a href="https://www.benzinga.com/news/earnings/24/06/39224137/gamestop-releases-q1-results-ahead-of-roaring-kitty-event-files-prospectus-to-raise-capital-via-equ">sell up to 75 million shares</a>.
GameStop released its first-quarter 2024 results early Friday ahead of its scheduled June 11 date. The company reported net sales of $881.8 million, down from $1.237 billion year-over-year. The net sales total missed a consensus estimate of $995.3 million. The company reported a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
GameStop shares dipped 22.5% to $36.07 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Trinity Place Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPHS#NYSE">TPHS</a>) jumped 165.4% to $0.3220 after declining around 11% on Thursday.</li>
<li>Leafly Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares gained 91.6% to $3.87.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares jumped 87.5% to $1.1606 on continued upward momentum after the stock regained Nasdaq compliance.</li>
<li>Asensus Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#NASDAQ">ASXC</a>) climbed 40.1% to $0.3291 after the company announced it will be acquired by KARL STORZ for $0.35 per share in cash.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) gained 29.3% to $0.7032.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) shares jumped 26% to $4.90 as the company reported the FDA approval of RYTELO&#x2122; (imetelstat), a first-in-class telomerase inhibitor, for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) gained 23.4% to $2.4899.</li>
<li>American Oncology Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) gained 22.6% to $2.0850. American Oncology Network recently announced the opening of Low Country Radiation in Waycross, Georgia.</li>
<li>MAIA Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NASDAQ">MAIA</a>) rose 21.2% to $4.0249. The company unveiled compelling efficacy data from its Phase 2 THIO-101 clinical trial.</li>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) gained 19.2% to $3.41 after the company received exclusive FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Nicotinamide Riboside Chloride in the treatment of Ataxia Telangiectasia.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) rose 18.8% to $4.11.</li>
<li>Oddity Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) gained 18.3% to $43.49 after the company approved a share buyback and raised its Q2 guidance.</li>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) jumped 14.3% to $2.64</li>
<li>Presto Automation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) rose 14.1% to $0.0866 after declining 27% on Thursday.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) gained 14.7% to $5.42. Yext is said to hire investment bankers to explore strategic alternatives, including a sale, Reuters reported.</li>
<li>Argan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) jumped 11.1% to $76.78 after the company reported better-than-expected first-quarter financial results.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) gained 9.6% to $1.9950 following better-than-expected quarterly earnings.</li>
<li>Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) rose 4.2% to $38.32 following better-than-expected first-quarter earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares dipped 65.6% to $3.87 after the United States Food and Drug Administration (FDA) imposed a full clinical hold on its Phase I/II trials for BMF-219, a diabetes treatment.</li>
<li>Barnes &amp; Noble Education, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) fell 35.3% to $0.2101 after the company announced final results of rights offering.</li>
<li>Scinai Immunotherapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) fell 31.3% to $2.7474. Scinai Immunotherapeutics regained compliance with Nasdaq minimum bid price requirement.</li>
<li>Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) fell 29.3% to $9.90. Volcon recently announced a 1-for-100 reverse stock split.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares fell 26.4% to $34.69 after jumping 49% on Thursday.</li>
<li>Hywin Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYW#NYSE">HYW</a>) dipped 24.7% to $0.4670.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares fell 24.2% to $4.24. MicroAlgo recently announced that it entered into convertible note purchase agreements with certain investors.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) dipped 23% to $1.5101. Actelis announced closing of exercise of warrants for $3 million gross proceeds.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) dipped 19.6% to $30.54 after the company announced it has appointed a new President and CEO and reaffirmed Q2 2025 guidance.</li>
<li>Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) fell 19.3% to $4.7699 after announcing a $12 million registered direct offering.</li>
<li>Bright Green Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares fell 18.7% to $0.2851 after declining around 8% on Thursday.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) declined 18.7% to $0.6916. Canaccord Genuity analyst John Newman maintained Seres Therapeutics with a Buy and lowered the price target from $15 to $10.</li>
<li>CEA Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEAD#NASDAQ">CEAD</a>) dipped 18% to $6.65.</li>
<li>Oil-Dri Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODC#NYSE">ODC</a>) fell 17.3% to $68.57 following third-quarter results.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) fell 17.1% to $1.07.</li>
<li>Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) shares declined 13.6% to $167.50 after the company reported weaker-than-expected results for its third quarter on Thursday.</li>
<li>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) shares dipped 13.4% to $30.17 after the company reported first-quarter earnings.</li>
<li>Moving iMage Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#NYSE">MITQ</a>) fell 10.3% to $0.6001 after declining 33% on Thursday. Moving iMage Technologies was recently awarded a multi-million dollar contract.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 10.2% to $17.56.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) fell 10.1% to $0.8001 as the company announced commencement of its previously announced rights offering.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) fell 9.2% to $8.36. Shares of precious metals companies traded lower amid a decline in gold and silver following US economic data.</li>
<li>Concrete Pumping Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBCP#NASDAQ">BBCP</a>) shares dipped 8% to $6.93 after posting weaker-than-expected second-quarter results.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) tumbled 8% to $24.75.</li>
<li>American Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSWA#NASDAQ">AMSWA</a>) declined 7.5% to $9.55 following quarterly results. B. Riley Securities analyst Zach Cummings maintained American Software with a Buy and lowered the price target from $16 to $14.</li>
<li>DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) shares fell 7.4% to $50.57. DocuSign reported better-than-expected earnings for its first quarter and the company&#8217;s board also authorized a $1 billion increase to its existing stock repurchase program. The company said it sees second-quarter billings in the range of $715 million to $725 million.</li>
<li>Impinj, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) fell 7.1% to $153.03.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) declined 5.2% to $24.13 after Morgan Stanley downgraded the stock from Overweight to Equal-Weight and lowered its price target from $28 to $27.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39226995/over-2m-bet-on-this-tech-stock-check-out-these-4-stocks-insiders-are-buying">Over $2M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying</a>

Intraday Update

AMSWA

AONC

ASNS

ASXC

BBCP

BGXX

BMEA

BNED

BRZE

CDXC

CEA INDUSTRIES INC by CEA Industries Inc.

CEAD

CLEU

DOCU

FFIE

GERN

GRRR

LFLY

MAIA

MITQ

MLGO

PRST

SCNI

SIFY

SMTC

SPWR

TPHS

UPST

VERO

VLCN

YEXT

Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Oppenheimer analyst Jeff Jones downgrades Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Outperform to Perform.

Oppenheimer Downgrades Seres Therapeutics to Perform

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 87.9% to $1.1 during Friday's regular session. The company's market cap stands at $7.0 million. </li>
<li>Asensus Surgical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#AMEX">ASXC</a>) stock moved upwards by 41.22% to $0.33. The market value of their outstanding shares is at $90.3 million. </li>
<li>American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) shares rose 29.41% to $2.2. The market value of their outstanding shares is at $22.4 million. </li>
<li>Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) shares rose 29.33% to $2.8. The market value of their outstanding shares is at $72.6 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock increased by 22.12% to $1.38. The market value of their outstanding shares is at $60.8 million. </li>
<li>Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) stock rose 21.07% to $4.71. The market value of their outstanding shares is at $2.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) stock declined by 63.1% to $4.16 during Friday's regular session. The company's market cap stands at $149.5 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares declined by 32.02% to $2.82. The market value of their outstanding shares is at $1.6 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 22.64% to $0.66. The company's market cap stands at $99.9 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) stock declined by 20.08% to $0.78. The company's market cap stands at $33.6 million. </li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) shares fell 18.24% to $34.83. The company's market cap stands at $938.0 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock declined by 17.7% to $0.09. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANEB

ARCT

INAB

NDRA

12 Health Care Stocks Moving In Friday's Intraday Session

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and lowers the price target from $15 to $10.

Canaccord Genuity Maintains Buy on Seres Therapeutics, Lowers Price Target to $10

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price target of $10....

Buy Rating Affirmed for Seres Therapeutics Amid Strong Clinical Outcomes for SER-155

Oppenheimer analyst Jeff Jones maintained a Hold rating on Seres Therapeutics (MCRB – Research Report) today. The company's shares closed yesterday...

Oppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

An update from Seres Therapeutics ( ($MCRB) ) is now available. Seres Therapeutics has finalized the sale of its VOWST business to Nestlé Health Sc...

Seres Therapeutics Streamlines Focus with VOWST Sale to Nestlé

Seres Therapeutics files for resale of common stock by holder

Seres Therapeutics gains amid takeover speculation

Seres cut to underweight by JP Morgan on Vowst sale

JPMorgan downgraded Seres Therapeutics (MCRB) to Underweight from Neutral. The firm notes that while it views the Vowst purchase by Nestle Health S...

Seres Therapeutics downgraded to Underweight from Neutral at JPMorgan

Warning: MCRB is at high risk of performing badly

NSRGF

NSRGY

Press Releases

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders

Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCRB, PALT, MRO on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Comments

Seres Therapeutics

Notizie

Ultime notizie per Seres Therapeutics (NASDAQ:MCRB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO